Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Medi Cal Claims topic
No spam. Unsubscribe anytime.
Board warns pharmacists: Medi‑Cal changes will require prescriber NPI and ICD‑10 codes — pharmacies could see rejected claims
Summary
Staff told the California State Board of Pharmacy on June 10 that Department of Health Care Services (Medi‑Cal) will require prescriber enrollment with a Type 1 NPI and, effective fall 2026, ICD‑10 diagnosis codes on pharmacy claims; members and public commenters warned that software gaps and privacy issues could cause claim rejections and delays in patient care.
Staff briefed the board that the Department of Health Care Services (DHCS) has issued guidance requiring prescribers to be enrolled in Medi‑Cal with their Type 1 national provider identifier (NPI) for pharmacy claims to adjudicate. Separately, DHCS plans to require ICD‑10 diagnosis codes on pharmacy claim adjudication effective in fall 2026; the requirement will apply to claims submitted on or after the implementation date, including refills for prescriptions written before the change.
Board members and public commenters warned that the changes could cause pharmacies to see rejected claims if the prescriber’s NPI or the ICD‑10 code is missing. Staff said draft communications are being coordinated across healing‑arts boards and that the Department of Consumer Affairs is collaborating with DHCS on outreach. Members urged the board to post guidance on its website, share materials with pharmacy schools, and work with DCA to create a landing page for licensees.
Commenters and members also raised privacy concerns: some ICD‑10 codes are highly specific and could disclose sensitive sexual‑behavior or gender‑affirming care details; members emphasized pharmacists should be mindful of privacy when entering diagnosis codes. Several speakers noted operational barriers: many pharmacy software systems need upgrades to transmit ICD‑10 codes reliably and some prescribers may not routinely include diagnosis codes on prescriptions. Members recommended proactive outreach, including encouraging pharmacists and prescribers to enroll for Medi‑Cal communications and to test software compatibility.
Public commenters described local experiences: one technician who translates at pharmacies reported employers requiring staff to use simplified language that can misstate clinical terms; a former board president suggested connecting outreach with cultural‑competency efforts. Staff said materials are being drafted for dissemination by affected healing‑arts boards.
Board members asked staff to continue coordinating with DCA and DHCS and to consider public-facing messages so patients know why a claim may be rejected at the pharmacy. Several members described the potential for operational disruption and urged timely communications to prescribers, pharmacies and schools.
